Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YJQAT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2024105206A1 32p-Avelu 2
|
|||||
| Synonyms |
WO2024105206A1 32p-Avelu 2
Click to Show/Hide
|
|||||
| Organization |
VINCERX PHARMA GMBH
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
TPP-Avelumab
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death 1 ligand 1 (CD274)
|
Antigen Info | ||||
| Payload Name |
Mdo-cpt
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
32p-Avelu Linker
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H69: 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 20 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Lung small cell carcinoma, Small cell lung cancer | NCI-H69 cells (-NE) | CVCL_1579 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H69: 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 20 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Lung small cell carcinoma, Small cell lung cancer | NCI-H69 cells (+NE) | CVCL_1579 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
1.0- 9.9 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 28 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (+NE) | CVCL_1600 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 28 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (-NE) | CVCL_1600 | ||
